Chris Garabedian, President and CEO Sarepta Therapeutics, Inc. (NASDAQ:SRPT), announced that the Phase IIb clinical study on its first product, eteplirsen, will have its results submitted to the FDA by the end of the year, with a launch slated for mid next-year if approved. He was speaking at the Canaccord Genuity 34th Annual Growth Conference at the Intercontinental Hotel in Boston, Massachusetts. Sarepta Therapeutics, Inc. … Continue reading Stocks in Focus : Sarepta Therapeutics (NASDAQ:SRPT), Google Inc (NASDAQ:GOOGL), B&G Foods Inc. (NYSE:BGS), Repros Therapeutics Inc. (NASDAQ:RPRX), Tejon Ranch (NYSE:TRC)